Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another?
<b<Background:</b< Kidney transplant recipients (KTRs) are likely to develop severe COVID-19 and are less well-protected by vaccines than immunocompetent subjects. Thus, the use of neutralizing anti–SARS-CoV-2 monoclonal antibodies (mAbs) to confer a passive immunity appears attractive in KTRs. <b<Methods:</b< This retrospective monocentric cohort study was conducted between 1 January 2022 and 30 September 2022. All KTRs with a weak antibody response one month after three doses of mRNA vaccine (anti spike IgG < 264 (BAU/mL)) have received tixagevimab-cilgavimab in pre-exposure (group 1), post-exposure (group 2) or no specific treatment (group 3). We compared COVID-19 symptomatic hospitalizations, including intensive care unit hospitalizations, oxygen therapy, and death, between the three groups. <b<Results:</b< A total of 418 KTRs had SARS-CoV-2 infection in 2022. During the study period, we included 112 KTRs in group 1, 40 KTRs in group 2, and 27 KTRs in group 3. The occurrence of intensive care unit hospitalization, oxygen therapy, and COVID-19 death was significantly increased in group 3 compared to group 1 or 2. In group 3, 5 KTRs (18.5%) were admitted to the intensive care unit, 7 KTRs (25.9%) needed oxygen therapy, and 3 KTRs (11.1%) died. Patients who received tixagevimab-cilgavimab pre- or post-exposure had similar outcomes. <b<Conclusions:</b< This retrospective real-life study supports the relative effectiveness of tixagevimab-cilgavimab on COVID-19 infection caused by Omicron, used as a pre- or post-exposure therapy. The continued evolution of Omicron variants has made tixagevimab-cilgavimab ineffective and reinforces the need for new therapeutic monoclonal antibodies for COVID-19 active on new variants..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Viruses - 16(2024), 3, p 381 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Anais Romero [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
COVID-19 |
|---|
| doi: |
10.3390/v16030381 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ09980381X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ09980381X | ||
| 003 | DE-627 | ||
| 005 | 20240414054417.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240414s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/v16030381 |2 doi | |
| 035 | |a (DE-627)DOAJ09980381X | ||
| 035 | |a (DE-599)DOAJe18e49b10bdd4f27bdf9d70144ce1275 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a QR1-502 | |
| 100 | 0 | |a Anais Romero |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a <b<Background:</b< Kidney transplant recipients (KTRs) are likely to develop severe COVID-19 and are less well-protected by vaccines than immunocompetent subjects. Thus, the use of neutralizing anti–SARS-CoV-2 monoclonal antibodies (mAbs) to confer a passive immunity appears attractive in KTRs. <b<Methods:</b< This retrospective monocentric cohort study was conducted between 1 January 2022 and 30 September 2022. All KTRs with a weak antibody response one month after three doses of mRNA vaccine (anti spike IgG < 264 (BAU/mL)) have received tixagevimab-cilgavimab in pre-exposure (group 1), post-exposure (group 2) or no specific treatment (group 3). We compared COVID-19 symptomatic hospitalizations, including intensive care unit hospitalizations, oxygen therapy, and death, between the three groups. <b<Results:</b< A total of 418 KTRs had SARS-CoV-2 infection in 2022. During the study period, we included 112 KTRs in group 1, 40 KTRs in group 2, and 27 KTRs in group 3. The occurrence of intensive care unit hospitalization, oxygen therapy, and COVID-19 death was significantly increased in group 3 compared to group 1 or 2. In group 3, 5 KTRs (18.5%) were admitted to the intensive care unit, 7 KTRs (25.9%) needed oxygen therapy, and 3 KTRs (11.1%) died. Patients who received tixagevimab-cilgavimab pre- or post-exposure had similar outcomes. <b<Conclusions:</b< This retrospective real-life study supports the relative effectiveness of tixagevimab-cilgavimab on COVID-19 infection caused by Omicron, used as a pre- or post-exposure therapy. The continued evolution of Omicron variants has made tixagevimab-cilgavimab ineffective and reinforces the need for new therapeutic monoclonal antibodies for COVID-19 active on new variants. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a monoclonal antibodies | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a kidney transplantation | |
| 653 | 0 | |a Microbiology | |
| 700 | 0 | |a Charlotte Laurent |e verfasserin |4 aut | |
| 700 | 0 | |a Ludivine Lebourg |e verfasserin |4 aut | |
| 700 | 0 | |a Veronique Lemée |e verfasserin |4 aut | |
| 700 | 0 | |a Mélanie Hanoy |e verfasserin |4 aut | |
| 700 | 0 | |a Frank Le Roy |e verfasserin |4 aut | |
| 700 | 0 | |a Steven Grange |e verfasserin |4 aut | |
| 700 | 0 | |a Mathilde Lemoine |e verfasserin |4 aut | |
| 700 | 0 | |a Dominique Guerrot |e verfasserin |4 aut | |
| 700 | 0 | |a Dominique Bertrand |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Viruses |d MDPI AG, 2009 |g 16(2024), 3, p 381 |w (DE-627)DOAJ000095435 |x 19994915 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g number:3, p 381 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/v16030381 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/e18e49b10bdd4f27bdf9d70144ce1275 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/1999-4915/16/3/381 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1999-4915 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2024 |e 3, p 381 | ||